

CORRECTION

Open Access



Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Chunmeng Wang^{1†}, Fengxia Shi^{1†}, Yang Liu¹, Yajing Zhang¹, Liang Dong¹, Xiang Li¹, Chuan Tong¹, Yao Wang¹, Liping Su², Jing Nie^{1*†} and Weidong Han^{1*†}

Correction to: *J Hematol Oncol* (2021) 14:106

<https://doi.org/10.1186/s13045-021-01120-3>

The original article [1] contained a minor error in the Additional file which has since been corrected.

Author details

¹Department of Bio-Therapeutic, The First Medical Centre in Chinese PLA General Hospital, Beijing, China. ²Department of Hematology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China.

Published online: 23 September 2021

Reference

1. Wang C, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. *J Hematol Oncol*. 2021;14:106. <https://doi.org/10.1186/s13045-021-01120-3>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1186/s13045-021-01120-3>.

*Correspondence: nnji2002@163.com; hanwdrsw69@yahoo.com

†Jing Nie and Weidong Han jointly supervise this work

†Chunmeng Wang and Fengxia Shi are co-first author

¹ Department of Bio-Therapeutic, The First Medical Centre in Chinese PLA General Hospital, Beijing, China

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.